非格司亭增强抗胸腺细胞球蛋白暴露后无关脐血移植中的T细胞清除
在275例首次接受异基因造血干细胞移植的患者中,研究主动型抗胸腺细胞球蛋白暴露对CD4+免疫重建的影响,并比较脐血移植与骨髓移植的差异。结果显示,非格司亭暴露通过增强中性粒细胞介导的抗胸腺细胞球蛋白细胞毒性(提高40倍),解释了脐血移植后T细胞清除增强的现象。
要点
- 主动型抗胸腺细胞球蛋白暴露量>10单位×天/毫升严重损害脐血移植后CD4+免疫重建,但对骨髓移植无此影响。
- 非格司亭暴露使中性粒细胞介导的抗胸腺细胞球蛋白细胞毒性提高40倍(0.5% vs 20%,P=0.002)。
- 研究提示需修订残留抗胸腺细胞球蛋白暴露患者中非格司亭的使用和/或时机。
核心结论
- 非格司亭暴露通过增强中性粒细胞介导的抗胸腺细胞球蛋白细胞毒性,解释了脐血移植后T细胞清除增强及CD4+免疫重建延迟的现象。
研究设计与样本
- 研究纳入2008年1月至2016年9月期间首次接受异基因造血干细胞移植的275例患者(脐血移植155例,骨髓移植120例;中位年龄7.8岁,范围0.16-19.2岁)。
- 采用多变量对数秩检验(校正协变量)分析主动型抗胸腺细胞球蛋白暴露对CD4+免疫重建的影响,并进行抗胸腺细胞球蛋白结合与细胞毒性实验。
主要发现
- 在主动型抗胸腺细胞球蛋白残留暴露<10单位×天/毫升时,脐血移植后CD4+免疫重建快于骨髓移植(P=0.018)。
- 在主动型抗胸腺细胞球蛋白残留暴露>10单位×天/毫升时,脐血移植后CD4+免疫重建严重受损(P<0.001),而骨髓移植后未受显著影响(P=0.74)。
- 抗胸腺细胞球蛋白结合与细胞毒性实验使用脐血和骨髓移植物来源的T细胞亚群、B细胞、自然杀伤细胞和单核细胞,未观察到差异。
- 非格司亭暴露使中性粒细胞介导的抗胸腺细胞球蛋白细胞毒性提高40倍(0.5% vs 20%,P=0.002)。
临床怎么用
- 作者认为,这些发现提示需修订残留抗胸腺细胞球蛋白暴露患者中非格司亭的使用和/或时机。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Residual antithymocyte globulin (ATG; Thymoglobulin) exposure after allogeneic hematopoietic (stem) cell transplantation (HCT) delays CD4+ T-cell immune reconstitution (CD4+ IR), subsequently increasing morbidity and mortality. This effect seems particularly present after cord blood transplantation (CBT) compared to bone marrow transplantation (BMT). The reason for this is currently unknown. We investigated the effect of active-ATG exposure on CD4+ IR after BMT and CBT in 275 patients (CBT n = 155, BMT n = 120; median age, 7.8 years; range, 0.16-19.2 years) receiving their first allogeneic HCT between January 2008 and September 2016. Multivariate log-rank tests (with correction for covariates) revealed that CD4+ IR was faster after CBT than after BMT with <10 active-ATG × day/mL (P = .018) residual exposure. In contrast, >10 active-ATG × day/mL exposure severely impaired CD4+ IR after CBT (P < .001), but not after BMT (P = .74). To decipher these differences, we performed ATG-binding and ATG-cytotoxicity experiments using cord blood- and bone marrow graft-derived T-cell subsets, B cells, natural killer cells, and monocytes. No differences were observed. Nevertheless, a major covariate in our cohort was Filgrastim treatment (only given after CBT). We found that Filgrastim (granulocyte colony-stimulating factor [G-CSF]) exposure highly increased neutrophil-mediated ATG cytotoxicity (by 40-fold [0.5 vs 20%; P = .002]), which explained the enhanced T-cell clearance after CBT. These findings imply revision of the use (and/or timing) of G-CSF in patients with residual ATG exposure.
引用
- de Koning C, Gabelich JA, Langenhorst J, et al. Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation. Blood Adv. 2018. PMID: 29535105. doi:10.1182/bloodadvances.2017015487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。